Abstract
Abstract WP343: Development of AneuScreen+TM, a First-of-its-Kind Blood-Blood Diagnostic for Intracranial Aneurysm
Stroke (1970), Vol.57(Suppl_1), WP343
02/2026
DOI: 10.1161/str.57.suppl_1.WP343
Abstract
Introduction: Intracranial aneurysm (IA) affects 3-5% of US population, and can lead to subarachnoid hemorrhage with high rates of morbidity and mortality. It is crucial to assess rupture risk so that clinicians can treat those at high risk of rupture and avoid risky surgeries for those with low risk. We are developing a low-cost, non-invasive blood RNA biomarker for aneurysm called AneuScreenTM.
Methods: We performed feature selection and preliminary model development using an existing dataset of 191 transcriptomes from individuals with IA to identify genes associated with IA rupture risk, determined by the PHASES score. We considered genes selected by differential expression analysis (edgeR), minimum redundancy-maximum relevance algorithm over 500 randomizations, and our previous studies. For the selected genes, we conducted analytical testing using pooled control human blood to ensure the designed probes met the signaling requirements. We subsequently tested the assay on a large group of clinical blood samples, collected under IRB approval from 4 US centers. The resultant expression data along with clinical data was used to refine the algorithm via a robust machine learning pipeline. Multiple feature selection strategies were applied independently across 500 stratified, random splits (80/20 train-test). Features selected in at least 50% of iterations were deemed stable. These features were then used to train and evaluate four classifiers, each optimized via 5-fold cross-validation in 500 randomizations in the training set. Model performance was assessed using ROC AUC, sensitivity, specificity, and accuracy. SHAP analysis was used to interpret model decisions based on the stable feature set.
Results: We identified 21 genes associated with aneurysm risk. A logistic regression model using expression levels achieved an AUC>0.8. The designed PCR probes met all analytical testing requirements, detectability, consistency across replicates, and linearity. After assay testing and model optimization, the best model was a logistic regression model that demonstrated high discriminative ability, with a mean ROC AUC of 0.83 and sensitivity>0.77 in testing. SHAP analysis reflects both genes and clinical features are important.
Conclusion: The AneuScreenTM risk assessment module was tested in a large cohort of individuals with IA and could predict high-risk cases with an AUC of 0.83, demonstrating a potential for using circulating blood to assess IA risk.
Details
- Title: Subtitle
- Abstract WP343: Development of AneuScreen+TM, a First-of-its-Kind Blood-Blood Diagnostic for Intracranial Aneurysm
- Creators
- Kerry Poppenberg - University at Buffalo, State University of New YorkTatsat Rajendra Patel - University at Buffalo, State University of New YorkJan-Karl Burkhardt - Penn Center for AIDS ResearchMaxim Mokin - University of South FloridaEdgar Samaniego - University of IowaJoshua Geiger - University of RochesterDoran Mix - University of RochesterElad Levy - University at Buffalo, State University of New YorkAdnan Siddiqui - University at Buffalo, State University of New YorkVincent Tutino - University at Buffalo, State University of New York
- Resource Type
- Abstract
- Publication Details
- Stroke (1970), Vol.57(Suppl_1), WP343
- DOI
- 10.1161/str.57.suppl_1.WP343
- ISSN
- 0039-2499
- eISSN
- 1524-4628
- Publisher
- Lippincott Williams & Wilkins
- Language
- English
- Date published
- 02/2026
- Academic Unit
- Neurology; Radiology; Iowa Neuroscience Institute; Neurosurgery
- Record Identifier
- 9985132066302771
Metrics
1 Record Views